United Capital Financial Advisors LLC Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

United Capital Financial Advisors LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 56.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,649 shares of the medical device company’s stock after purchasing an additional 6,401 shares during the period. United Capital Financial Advisors LLC’s holdings in DexCom were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Versant Capital Management Inc purchased a new position in shares of DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on DXCM shares. Mizuho started coverage on DexCom in a research note on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective for the company. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Citigroup increased their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Finally, Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $99.00.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $68.59 on Friday. The stock has a market cap of $26.90 billion, a price-to-earnings ratio of 47.97, a PEG ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $139.24. The stock’s 50 day moving average price is $74.98 and its 200 day moving average price is $76.61.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.